Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big Pharma Amgen pays US$2 Billion for Phase 1 company

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Jan 05, 2023 5:04pm

270 Views

Post# 35205635

Big Pharma Amgen pays US$2 Billion for Phase 1 company

January 05, 2023 - Amgen starts the new year with a bang, licensing-in Synaffix Phase-1 ADC technology for US $2 billion - the largest ADC licensing deal to date.

https://endpts.com/amgen-kicks-off-2023-dealmaking-with-busy-adc-upstart-synaffix/

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles